GPT and metabolic dysfunction-associated steatotic liver disease: On the other hand, the significant lipid-lowering potency (LDL concentration reduction from 171 ± 24 to 95 ± 36 mg/dl; p < 0.001) of the combined therapy consisting of 10 mg of rosuvastatin and 5 mg of ezetimibe did not lead to any significant changes in aminotransferase activities (ALT: 71 ± 37 vs. 66 ± 37 IU/L; p = 0.051, AST: 47 ± 35 vs. 37 ± 17 IU/L; p = 0.215) in subjects with NAFLD during the 48-week treatment period [97].